Acquisition to boost Genzyme's surgical business
This article was originally published in Clinica
Genzyme's General Division plans to acquire Deknatel Snowden Pencer (DSP), a privately-held surgical products company, for $250 million in cash. The proposed purchase, which is expected to close by the end of June, should add $50 million to Genzyme's revenue this year. Genzyme's 1995 turnover was $379 million.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.